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Abstract
Background: The present study aims to explore whether Schisandra chinensis Baill, a Chinese, medicinal herb can alleviates
high-fat-diet-inducing non-alcoholic steatohepatitis in rats.
Materials and Methods: In the study, 24, male Wister rats with body weight between 180-220g, were included. The rats were randomly divided
into four groups: model group, normal control group, rosiglitazone group, and Schisandra chinensis Baill group. The treatment lasted for 56, days.
The high-fat diet used in the present study includes 25% lard, 2%, cholesterol 0.5%, sodium cholate, and 25%, Tween-80. The hepatic levels of
superoxide dismutase (SOD), and malondialdehyde (MDA); the serum levels of total cholesterol (TC), and low-density lipoprotein cholesterol
(LDLC), were detected.
Results: We found that the hepatic levels of SOD were significantly lower, and the serum levels of TC, LDLC as well as, the hepatic levels of
MDA in model group were significantly higher than those of normal control group; rosiglitazone group and Schisandra chinensis Baill group
(P<0.05), indicates that non-alcoholic steatohepatitis rats were successfully induced by high-fat diet. Schisandra chinensis Baill group presented a
significant lower serum levels of LDLC, than rosiglitazone group (P<0.05); and the hepatic levels of SOD in Schisandra chinensis Baill group
were significantly lower than rosiglitazone group (P<0.05). However, no significant difference existed between Schisandra chinensis Baill group,
and rosiglitazone group on the hepatic levels of MDA and the serum levels of TC (P>0.05).
Conclusion: It is then concluded that Schisandra chinensis Baill can significantly alleviate the non-alcoholic steatohepatitis of the rats induced by
high-fat diet, and it may be used as a complementary therapy for rosiglitazone.
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Introduction
With the epidemic of obesity, and the metabolic syndrome, non-alcoholic fatty liver disease has become the most common liver
disease, and leading cause of altered liver enzymes in Western countries. (Bellentani et al., 2000; Browning et al., 2004). Due to the high
prevalence of the non-alcoholic fatty liver disease, it is impossible to perform liver biopsy in a large population at risk to predict steatohepatitis
(Musso et al., 2011). Unlike simple steatosis, which is characterized by a relatively favorable clinical caurse; non-alcoholic steatohepatitis is more
likely to cirrhosis, and hepatocellular carcinoma. (Cohen et al., 2011; Starley et al., 2010) Non-alcoholic fatty liver disease has been found
associated with oxidative hepatocellular damage, inflammation, and activation of fibro-genesis, such as non-alcoholic steato-hepatitis. (Day,
2006). It has been found that the “two-hit” mechanism is included in the development of non-alcoholic steato-hepatitis, in which, liver steatosis
constitutes the “first hit”, and it is accompanied by obesity, and metabolic disruptions inducing excessive hepatic lipid accumulation. (Day and
James, 1998) Liver steatosis was found to likely increase the vulnerability of the liver to a “second hit”, in the form of oxidative stress or,
pro-inflammatory insults that result in non-alcoholic steato-hepatitis (Park et al., 2012). Non-alcoholic fatty liver disease includes a spectrum
from simple steatosis to non-alcoholic steato-hepatitis. The simple steatosis, and non-alcoholic steato-hepatitis are different in histological, and
patho-physiological viewpoint. (Yilmaz, 2012). The increased formation of reactive oxygen species from inflammatory cell activation,
mitochondrial dysfunction, and the induction of microsomal, v-oxidation were found to change the intracellular redox state, and lead to hepatic
lipid per-oxidation and liver injury. The liver injury has been found to be induced by the reactive oxygen species through interaction with
bio-molecules, which will then change the function. (Mato et al., 2002). A “footprint”, for oxidative stress was found to increase in liver biopsy
samples of the patients with non-alcoholic fatty liver disease. (Sanyal et al., 2001). The intervention, that function to suppress oxidative stress and
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pro-inflammatory responses may possess the potential to prevent the development of non-alcoholic steato-hepatitis (Park et al., 2012).
Schisandra chinensis Baill, as a key Chinese medicinal herb, is native to northern and northeastern China. Its Chinese name emanates
from the fact that, its berries possess all the basic five flavors: salty, sweet, sour, and pungent (spicy), and bitter. The active components in
Schisandra chinensis Baill includes: deoxyschisandrin, gamma-schisandrin, schizandrin, and gomisin A. Both deoxyschisandrin, and
gamma-schisandrin were proved to have protective effect against CCl4-induced hepatic damage, and ultra-high pressure extraction (UHPE), is an
efficient extraction method for the extraction of effective ingredients from Schisandra chinensis Baill (Liu et al., 2009), and the aqueous extract
of Schisandra chinensis Baill has been found to possess dual effects on the enzyme activity of CYP3A in rats in vivo (Chen et al., 2010).
The present study was designated to explore whether Schisandra chinensis Baill, a Chinese medicinal herb, can alleviates
high-fat-diet-inducing non-alcoholic steatohepatitis in rats.
Materials and methods
Animals and group
Twenty-four male Wister rats (weighing 180-220g), were provided by the Laboratory, Animal Center of Zhejiang University of
Chinese Medicine (Hangzhou, China). The animals were kept in a room under a 12hrs light–12hrs, dark cycle and environmentally controlled
conditions of 22±2°C. The research was carried out according to the National Research Council's protocol for the care and use of laboratory
animals. After all the animals were acclimatized a week before the experiment, the rats were randomly divided into four groups: model group
(high-fat diet + intra-gastric distilled water for 56, days), normal control group (standard diet + intra-gastric distilled water for 56 days),
rosiglitazone group (high-fat diet + intragastric rosiglitazone, 0.5mg/kg/day for 56, days), and Schisandra chinensis Baill group (high-fat diet +
intra-gastric Schisandra chinensis Baill, 100mg/kg/day for 56, days). Food intake was recorded throughout the 8-week treatment. A high-fat diet
includes 25%, lard, 2%, cholesterol 0.5%, sodium cholate and 25%, Tween-80, which were provided by the Laboratory, Animal Center of
Zhejiang University of Chinese Medicine (Hangzhou, China). Schisandra chinensis Baill was provided, and identified by Zhejiang University of
Chinese Medicine (Hangzhou, China). 20g, of Schisandra chinensis Baill was extracted by refluxing with 250ml of water for 30min., followed by
filtration. The same extraction procedures were repeated once. The obtained solution was combined, and condensed to a concentration of 1g/ml,
which was then freeze dried, and extract of Schisandra chinensis Baill gotten. The rosiglitazone used in the present study was purchased from
Jinan Zhongke Yitong Chemical Co., Ltd., China.
Sample collection and detection of parameters
On the day following the final administration, all the rats were sacrificed after 12hrs of fasting. The serum and liver samples were taken
after the rats were anesthetized with diethyl ether. The serum obtained was stored at −80 ◦C, until assay. The liver tissues were rapidly dissected, 
cut and fixed in 10%, formaldehyde saline solution for the determination of the hepatic levels of malondialdehyde (MDA), and superoxide
dismutase (SOD), using commercial assay kits (Sigma-Aldrich, USA), according to manufacturer instructions. The serum levels of total
cholesterol (TC), and low-density lipoprotein cholesterol (LDLC), were determined by enzymatic colorimetric method using commercial standard
enzymatic assay kits (Biosino, Bio-technology & Sience Inc.), according to the manufacturer’s instruction. All the measurements were carried out
in duplicate and conducted according to the manufacturer’s instruction. Both intra- and inter-assay coefficients of variation were less than 10%.
Statistical analysis
All the data were analyzed with Statistical Package for Social Sciences (SPSS 13.0 for Windows). Analysis of variance (ANOVA), was
employed for analyzing all the data. A 5%, significance level (P<0.05), and two-tailed tests were used for all hypothesis tests.
Results
The hepatic levels of SOD
As shown in Figure 1, in model group, the hepatic levels of SOD were notably lower than those of normal control group, rosiglitazone
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group, and Schisandra chinensis Baill group (P<0.05). In the normal control group, the hepatic levels of SOD were significantly higher than those
of rosiglitazone group, and Schisandra chinensis Baill group (P<0.05). The hepatic levels of SOD in Schisandra chinensis Baill group were
significantly lower than rosiglitazone group (P<0.05).
Figure. 1. The hepatic levels of superoxide dismutase (SOD): model group (high-fat diet + intragastric distilled water for 56, days), normal
control group (standard diet + intragastric distilled water for 56 days), rosiglitazone group (rosi- group: high-fat diet + intra-gastric rosiglitazone,
0.5mg/kg/day for 56, days) and Schisandra chinensis Baill group (schi-group: high-fat diet + intragastric Schisandra chinensis Baill,
100mg/kg/day for 56, days). Data were shown as mean ± SD. (n=6 in each group). The significant difference was set at a P<0.05, compared with
the model group; b p <0.05, compared with normal control group; c P<0.05, compared with rosiglitazone group.
The hepatic levels of MDA
As shown in Figure 2, in the model group, the hepatic levels of MDA were remarkably higher than those of normal control group;
rosiglitazone group, and Schisandra chinensis Baill group (P<0.05). In the normal control group, the hepatic levels of MDA were significantly
lower than those of rosiglitazone group and Schisandra chinensis Baill group (P<0.05). There existed no significant difference on the hepatic
levels of MDA between Schisandra chinensis Baill group and rosiglitazone group (P>0.05).
Figure. 2. The hepatic levels of malondialdehyde (MDA): model group (high-fat diet + intra-gastric distilled water for 56, days); normal control
group (standard diet + intra-gastric distilled water for 56, days); rosiglitazone group (rosi- group: high-fat diet + intra-gastric rosiglitazone,
0.5mg/kg/day for 56, days); and Schisandra chinensis Baill group (schi-group: high-fat diet + intra-gastric Schisandra chinensis Baill,
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100mg/kg/day for 56, days). Data were shown as mean ± SD. (n=6 in each group). The significant difference was set at a P<0.05, compared with
model group; b p <0.05, compared with normal control group; c P<0.05, compared with rosiglitazone group.
The serum levels of TC
As shown in Figure 3, the serum levels of TC in model group were significantly higher than those of normal control group, rosiglitazone
group, and Schisandra chinensis Baill group (P<0.05). In the normal control group, the serum levels of TC were significantly lower than those of
rosiglitazone group and Schisandra chinensis Baill group (P<0.05). No significant difference existed between Schisandra chinensis Baill group,
and rosiglitazone group on the serum levels of TC (P>0.05).
Figure. 3. The serum levels of total cholesterol (TC): model group (high-fat diet + intragastric distilled water for 56, days); normal control group
(standard diet + intra-gastric distilled water for 56, days), rosiglitazone group (rosi- group: high-fat diet + intra-gastric rosiglitazone,
0.5mg/kg/day for 56, days); and Schisandra chinensis Baill group, (schi-group: high-fat diet + intragastric Schisandra chinensis Baill,
100mg/kg/day for 56, days). Data were shown as mean ± SD. (n=6 in each group). The significant difference was set at a P<0.05, compared with
model group; b p <0.05, compared with normal control group; c P<0.05, compared with rosiglitazone group.
The serum levels of LDLC
As shown in Figure 4, in the model group, the serum levels of LDLC were markedly higher than those of normal control group,
rosiglitazone group, and Schisandra chinensis Baill group (P<0.05). The serum levels of LDLC in the normal control group were significantly
lower than those of rosiglitazone group and Schisandra chinensis Baill group (P<0.05). Schisandra chinensis Baill group presented significantly
lower serum levels of LDLC than rosiglitazone group (P<0.05).
Figure. 4. The serum levels of low-density lipoprotein cholesterol (LDLC): model group (high-fat diet + intragastric distilled water for 56, days);
normal control group (standard diet + intra-gastric distilled water for 56, days); rosiglitazone group (rosi- group: high-fat diet + intra-gastric
rosiglitazone, 0.5mg/kg/day for 56, days); and Schisandra chinensis Baill group (schi-group: high-fat diet + intra-gastric Schisandra chinensis
Baill, 100mg/kg/day for 56, days). Data were shown as mean ± SD. (n=6 in each group). The significant difference was set at a P<0.05, compared
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with model group; b p <0.05, compared with normal control group; c P<0.05, compared with rosiglitazone group.
Discussion
Non-alcoholic fatty liver disease, defined by the presence of liver fat deposit associated with the metabolic syndrome as well as, the
systemic insulin resistance (Alisi et al., 2012; Alisi and Nobili, 2012), is a major public health issue for the high prevalence. The oxidative, and
nitrosative stress were also found in the animal experiment.(Armutcu et al., 2005) Consequently, it is important to create some noninvasive
methods for the diagnosis, and follow-up of non-alcoholic steato-hepatitis; and effective treatment to alleviate the progression of non-alcoholic
steato-hepatitis are urgently needed. Some promising results have been shown for anti-oxidants (Armstrong et al., 2010; Sanyal et al., 2010; Violi
and Cangemi, 2010). However, no therapeutic trial has yielded to demonstrate the results in the progression of liver damage. (Musso et al., 2010)
In 2005, a simple, economic, and effective non-aqueous capillary electrophoresis separation and detection method, has been established
for the quantification of deoxyschizandrin, and gamma-schizandrin in Schisandra chinensis Baill (Anjia et al., 2005). In a previous study, four
bioactive lignans (schisandrin, schisantherin, deoxyschizandrin, and gamma-schizandrin) in Schisandra chinensis Baill were determined using
Slice-scan method together with the new quantitative strategy, and satisfactory results have been obtained (Qi et al., 2009) Schisandrin, the main
active ingredient isolated from Schisandra chinensis Baill, has been found to have anti-inflammatory properties through inhibition of nitric oxide
(NO), production, prostaglandin E(2) (PGE(2)), release, cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) expression,
which in turn results from the inhibition of nuclear factor-kappaB (NF-kappaB), c-Jun N-terminal kinase (JNK), and p 38, mitogen-activated
protein kinase (MAPK), activities in a RAW 264.7, macrophage cell line. (Guo et al., 2008). In the present study, we found that the hepatic levels
of SOD were significantly lower, and the serum levels of TC, LDLC as well as, the hepatic levels of MDA in model group were significantly
higher than those of normal control group, rosiglitazone group, and Schisandra chinensis Baill group, indicating the non-alcoholic steatohepatitis
rats were successfully induced by high-fat diet. Schisandra chinensis Baill group presented significant lower serum levels of LDLC, than
rosiglitazone group; and the hepatic levels of SOD in Schisandra chinensis Baill group were significantly lower than rosiglitazone group.
However, no significant difference existed between Schisandra chinensis Baill group and rosiglitazone group on the hepatic levels of MDA and
the serum levels of TC. Although Schisandra chinensis Baill failed to alter some parameters as marked as rosiglitazone, we found it can
significantly alleviate the non-alcoholic steatohepatitis of the rats induced by high-fat diet, hence merits further study. Further study will be
conducted on the mechanism involved in the process of Schisandra chinensis Baill alleviating the non-alcoholic steatohepatitis of the rats induced
by high-fat diet.
Conclusion
Schisandra chinensis Baill can significantly alleviate the non-alcoholic steatohepatitis of the rats induced by high-fat diet, and may be
used as complementary therapy for rosiglitazone.
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